Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lindsay M Wallace

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Molecular Therapy. Nucleic Acids|April 18, 2013
Dose-dependent Toxicity of Humanized Renilla reniformis GFP (hrGFP) Limits Its Utility as a Reporter Gene in Mouse MuscleLindsay M Wallace, Andrew Moreo, K Reed Clark, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 7, 2011
RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1)Lindsay M Wallace, Sara E Garwick-Coppens, Rossella Tupler, et al.
Brain, Behavior, and Immunity|November 28, 2017
High mobility group box-1 (HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammationKristina A Kigerl, Wenmin Lai, Lindsay M Wallace, et al.
Molecular Therapy. Advances|May 15, 2026
Development of <i>in vitro</i> potency assays for AAV-based gene silencing therapies targeting FSHD and CMT1AJason McCoy, Lindsay M Wallace, Bi Zhou, et al.
Annals of Neurology|March 30, 2011
DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivoLindsay M Wallace, Sara E Garwick, Wenyan Mei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 18, 2012
RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapyLindsay M Wallace, Jian Liu, Jacqueline S Domire, et al.
Plos One|March 6, 2015
Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequencesEugénie Ansseau, Jacqueline S Domire, Lindsay M Wallace, et al.
Human Molecular Genetics|February 8, 2017
Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4Jocelyn O Eidahl, Carlee R Giesige, Jacqueline S Domire, et al.
Molecular Therapy. Nucleic Acids|May 1, 2014
RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A MiceJian Liu, Lindsay M Wallace, Sara E Garwick-Coppens, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Molecular Therapy. Nucleic Acids|April 18, 2013
Dose-dependent Toxicity of Humanized Renilla reniformis GFP (hrGFP) Limits Its Utility as a Reporter Gene in Mouse MuscleLindsay M Wallace, Andrew Moreo, K Reed Clark, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 7, 2011
RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1)Lindsay M Wallace, Sara E Garwick-Coppens, Rossella Tupler, et al.
Brain, Behavior, and Immunity|November 28, 2017
High mobility group box-1 (HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammationKristina A Kigerl, Wenmin Lai, Lindsay M Wallace, et al.
Molecular Therapy. Advances|May 15, 2026
Development of <i>in vitro</i> potency assays for AAV-based gene silencing therapies targeting FSHD and CMT1AJason McCoy, Lindsay M Wallace, Bi Zhou, et al.
Annals of Neurology|March 30, 2011
DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivoLindsay M Wallace, Sara E Garwick, Wenyan Mei, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 18, 2012
RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapyLindsay M Wallace, Jian Liu, Jacqueline S Domire, et al.
Plos One|March 6, 2015
Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequencesEugénie Ansseau, Jacqueline S Domire, Lindsay M Wallace, et al.
Human Molecular Genetics|February 8, 2017
Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4Jocelyn O Eidahl, Carlee R Giesige, Jacqueline S Domire, et al.
Molecular Therapy. Nucleic Acids|May 1, 2014
RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A MiceJian Liu, Lindsay M Wallace, Sara E Garwick-Coppens, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Pageof 2